Feature | Thrombectomy Devices | June 12, 2015

Ultrasound to Breakup STEMI Causing Clots in Heart Attack Patients

Breakthrough research at ASE demonstrates contrast ultrasound may help restore some blood flow in myocardial infarction patients

STEMI, ultrasound to treat heart attacks, ultrasound to treat STEMI

June 12, 2015 - Researchers presented data at the 2015 American Society of Echocardiography (ASE) meeting in June showing intravenous microbubbles combined with transthoracic ultrasound can help restore blood flow to the heart muscle in acute ST-segment elevation myocardial infarction (STEMI), potentially preserving heart function in these patients.  This sonothrombolysis method uses ultrasound to burst ultrasound contrast bubbles inside the STEMI-causing clot, which creates micro-channels for blood flow within the clot.  

This method also may help reduce the "no-reflow"phenomena following percutaneous coronary intervention (PCI). This is believed to be caused by stenting sending clot emboli downstream into the capillaries. Using ultrasound as a therapy device also has advantages of imaging the anatomy simultaneously. 
 
Nearly 250,000 people experience STEMI heart attacks annually and one of the most important factors for recovery is quick treatment to reduce blockages and restore blood flow to prevent muscle death. While this sonothrombolysis technique has previously been studied in animals, this is the first study to test the method in humans.
 
"This is a breakthrough, first-in-humans study in patients with acute myocardial infarction that has the potential to revolutionize the treatment of these patients and other acute thrombotic diseases such as stroke and deep venous thrombosis," said senior author Wilson Mathias, Jr., M.D., University of Sí£o Paulo Medical School in Sí£o Paulo, Brazil.  
 
The research team used a standard diagnostic ultrasound transducer to apply high mechanical index impulses during a continuous infusion of Definity (produced by Lantheus) microbubble contrast agent in a large emergency room setting. The combination of ultrasound and echo contrast were used both immediately prior to and immediately following emergent PCI.  Those patients who were randomized to one of two sonothrombolysis groups showed both higher recanalization rates at initial angiography and improving cardiac function. Most importantly, no patient deaths were experienced and door-to-dilation times were not affected, demonstrating both safety and feasibility for this technique. 
 
Ultrasound contrast is composed of microscopic lipid spheres that are injected into the patient's bloodstream.  The bubbles return the ultrasonic sound waves used to form an image and enhance the blood.  The ultrasonic waves also shatter the bubbles and it is the physics of the cavitaion caused by breaking bubbles that enables the microscopic breakdown of the thrombus. 
 
Researchers on the study, "Safety and Feasibility of Diagnostic Ultrasound High Mechanical Index Impulses in Restoring Epicardial Flow in Acute ST Segment Elevation Myocardial Infarction in Humans," included Bruno Garcia Tavares, Jeane M. Tsutsui, Miguel Osmar Aguiar, Diego Garcia, Mucio T. Oliveira, Alexandre Soeiro, Jose C. Nicolau, Pedro Lemos, Roberto Kalil, and Wilson Mathias, Jr. of Heart Institute (InCor) - University of Sí£o Paulo Medical School in Sí£o Paulo, Brazil; and  Thomas R. Porter of the University of Nebraska Medical Center in Omaha.
 
In future technology sessions at ASE, there were discussions on developing new echo contrast agents with embedded lytic therapy in the lipid shell to deliver lyics only to the targeted anatomy.   
 
For more information: www.asescientificsessions.org
 

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init